Back pain associated with a new coronavirus infection COVID-19

Putilina M.V.; Petrikeeva A.E.; Ariskina I.E.

doi:https://doi.org/10.17116/pain20222001142

Close metadata

Recommended articles:

Muscle relaxant selection criteria for musculoskeletal pain. Russian Journal of Pain. 2024;(4):55-64

Improving the effectiveness of treatment of patients with post-stroke aphasia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):22-28

Diagnosis of neuroinfections in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11-2):51-59

Localization features of FAP-positive activated stromal cells in fibrosis in patients with new coronavirus infection COVID-19. Russian Journal of Archive of Pathology. 2024;(6):5-14

The role of drug Cytoflavin in the correction of dysautonomia in patients with post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):140-146

The results of a multicenter open observational study of the efficacy and safety of the dietary supplement Neururidine N in patients with acute nonspecific lower back pain in daily outpatient practice (the NEURO-N study). S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):158-164

Laparoscopic appendectomy for appendiceal mucocele in a patient with COVID-19. Endoscopic Surgery. 2024;(6):41-45

Long-term outcomes in patients after hospital treatment for COVID-19 (three-year follow-up data). Russian Journal of Preventive Medicine. 2024;(12):114-121

Selective anosmia for monomolecular odorants in a cohort of young individuals. Russian Rhinology. 2024;(4):262-268

The results of the examination of patients with chronic generalized periodontitis after novel coronavirus infection. Russian Journal of Stomatology. 2024;(4):18-22

Abstract:

The article describes a clinical case of a patient with pain in the lower back after suffering a coronavirus infection COVID-19. The purpose of the observation was to study the association of COVID-19 with pain in the lower back, as well as the compliance of complaints and the clinical picture with the criteria for diagnosing postcoid syndrome. Possible therapy strategy developed. The use of NSAID Meloxicam (Amelotex), myoreraxant Tolperisone (Calmirex), and the antioxidant Cytoflavin contributed to a rapid regression of symptoms and an improvement in the patient’s general condition. There were no reported side effects or complications of therapy. Additionally, no correction of antihypertensive therapy was required.

Keywords:

COVID-19

lower back pain

post-lobe syndrome

Meloxicam (Amelotex)

Tolperisone (Calmirex)

Cytoflavin

Authors:

Putilina M.V.

Pirogov Russian National Research Medical University

ORCID: 0000-0002-8655-8501

Petrikeeva A.E.

Zhadkevich City Clinical Hospital of the Moscow Healthcare Department

Ariskina I.E.

Zhadkevich City Clinical Hospital

Received:

11.01.2022

Accepted:

12.01.2022

Close metadata

References:

Gromova OA, Torshin IYu, Semenov VA, Putilina MV, Chuchalin AG. Direct and indirect neurological manifestations of COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(11):11-21. (In Russ.). https://doi.org/10.17116/jnevro202012011111
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. Epub 2021 Mar 22. PMID: 33753937. https://doi.org/10.1038/s41591-021-01283-z
Disser NP, De Micheli AJ, Schonk MM, Konnaris MA, Piacentini AN, Edon DL, Toresdahl BG, Rodeo SA, Casey EK, Mendias CL. Musculoskeletal Consequences of COVID-19. The Journal of Bone and Joint Surgery. 2020;102(14):1197-1204. https://doi.org/10.2106/JBJS.20.00847
Bakılan F, Gökmen İG, Ortanca B, Uçan A, Güvenç ŞE, Mutlu FŞ, Gökmen HM, Ekim A. Musculoskeletal symptoms and related factors in postacute COVID-19 patients. Int J Clin Pract. 2021;75:e14734. https://doi.org/10.1111/ijcp.14734
Putilina MV, Grishin DV. SARS-CoV-2 (COVID-19) as a predictor of neuroinflammation and neurodegeneration: potential therapy strategies. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):58-64. (In Russ.). https://doi.org/10.17116/jnevro202012008258
Karaarslan F, Demircioğlu GF, Kardeş S. Postdischarge rheumatic and musculoskeletal symptoms following hospitalization for COVID-19: prospective follow-up by phone interviews. Rheumatol Int. 2021;41:1263-1271. https://doi.org/10.1007/s00296-021-04882-8
Putilina MV. Endothelium as a target for new therapeutic strategies in cerebral vascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(10):122-130. (In Russ.). https://doi.org/10.17116/jnevro2017117101122-130
Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, Walshaw C, Kemp S, Corrado J, Singh R, Collins T, O’Connor RJ, Sivan M. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021;93:1013-1022. https://doi.org/10.1002/jmv.26368
Carfì A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603-605. https://doi.org/10.1001/jama.2020.12603
Putilina MV, Vechorko VI, Grishin DV, Sidelnikova LV. Acute cerebrovascular accidents associated with SARS-CoV-2 coronavirus infection (COVID-19). S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(12):109-118. (In Russ.). https://doi.org/10.17116/jnevro2020120121109
Shah S, Danda D, Kavadichanda C. Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. Rheumatol Int. 2020;40:1539-1554. https://doi.org/10.1007/s00296-020-04639-9
Obbarius A, Fischer F, Liegl G, Obbarius N, van Bebber J, Hofmann T, Rose M. A Step Towards a Better Understanding of Pain Phenotypes: Latent Class Analysis in Chronic Pain Patients Receiving Multimodal Inpatient Treatment. J Pain Res. 2020;13:1023-1038. https://doi.org/10.2147/JPR.S223092
Šagát P, Bartík P, Prieto González P, Tohănean DI, Knjaz D. Impact of COVID-19Quarantine on Low Back Pain Intensity, Prevalence, and Associated Risk Factors among Adult Citizens Residing in Riyadh (Saudi Arabia): A Cross-Sectional Study. Int J Environ Res Public Health. 2020;17(19):7302. PMID: 33036287; PMCID: PMC7579188. https://doi.org/10.3390/ijerph17197302
Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med. 2020;18(1):100. PMID: 32093722; PMCID: PMC7038594. https://doi.org/10.1186/s12967-020-02269-0
Putilina MV, Baranova OA. Results of the multicenter clinical and epidemiological observational program «GLOBUS» (determination of the prevalence of dizziness and assessment of therapy regimens at the outpatient level). S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(5):33-38. (In Russ.).
Wong AY, MacKenna B, Morton CE. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: An OpenSAFELY cohort analysis based on two cohorts Annals of the Rheumatic Diseases. 2021;80:943-951. https://doi.org/10.1136/annrheumdis-2020-219517
Onuora S. NSAIDs not linked to worse COVID-19 outcomes. Nat Rev Rheumatol. 2021;17:378. https://doi.org/10.1038/s41584-021-00645-8
Abu Esba, L.C., Alqahtani, R.A., Thomas, A. Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study. Infect Dis Ther. 2021;10:253-268. https://doi.org/10.1007/s40121-020-00363-w
Sharpe KP, Berkowitz R, Tyndall WA, Boyer D, McCallum SW, Mack RJ, Du W. Safety, Tolerability, and Effect on Opioid Use of Meloxicam IV Following Orthopedic Surgery. J Pain Res. 2020;13:221-229. https://doi.org/10.2147/JPR.S216219
Colberg K, Hettich M, Sigmand R. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: A comparison with intramuscular and oral diclofenac in patients with acute lumbago. Curr Med Res Opin. 1996;13:363-377. https://doi.org/10.1185/03007999609111556
Viscusi ER, Gan TJ, Bergese S, et al. Intravenous meloxicam for the treatment of moderate to severe acute pain: A pooled analysis of safety and opioid-reducing effects. Reg Anesth Pain Med. 2019;44:360-368. https://doi.org/10.1136/rapm-2018-100184
Berkowitz RD, Steinfeld R, Sah AP. Efficacy and safety of preoperative meloxicam IV in primary total knee arthroplasty. Reg Anesth Pain Med. 2020;45(7):566-578. https://doi.org/10.1136/rapm-2020-ASRAannualmtg2020
Jahr JS, Searle S, McCallum S, Mack R, Minger K, Freyer A, Du W, Hobson S. Platelet Function: Meloxicam Intravenous in Whole Blood Samples From Healthy Volunteers. Clinical Pharmacology in Drug Development. 2020;9:841-848. https://doi.org/10.1002/cpdd.772
Putilina MV, Ivanova MP, Petrikeeva AE, Berns SA. Difficulties in diagnosing sacroiliitis in young patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):117-126. (In Russ.). https://doi.org/10.17116/jnevro2020120081117
Shirokov VA, Potaturko AV, Goncharenko IM. Safety and effectiveness of administration of Amelotex in trigger zones in lower lumbar pain syndrome. Effective Pharmacotherapy. 2013;48:48-52. (In Russ.).
Shavlovskaya OA, Romanov ID. Evaluation of the efficacy and tolerability of complex therapy for non-specific low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7):63-67. (In Russ.). https://doi.org/10.17116/jnevro202012007163
Gromova OA, Torshin IYu, Putilina MV, Maiorova LA, Semenov VA. On the mechanisms of the synergistic action of tolperisone, meloxicam and B vitamins in the treatment of peripheral pain syndromes. Medical Council. 2020;(8):54-64. (In Russ.). https://doi.org/10.21518/2079-701X-2020-8-54-64
Fischoff D, Spivakovsky S. Are pharmacological treatments for oro-facial pain effective? Evid Based Dent. 2018;19(1):28-29. https://doi.org/10.1038/sj.ebd.6401294
Tabeeva GR. Muscle relaxants as alternative analgesics in the treatment of nonspecific back pain. Neurology, Neuropsychiatry, Psychosomatics. 2017;9(2):89-94. (In Russ.). https://doi.org/10.14412/2074-2711-2017-2-89-94
Putilina MV, Teplova NV, Bairova KI, Petrikeeva AE, Shabalina NI. The result of prospective randomized study CITADEL — the efficacy and safety of drug cytoflavin in postcovid rehabilitation. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(10):45-51. (In Russ.). https://doi.org/10.17116/jnevro202112110145
El-Tallawy SN, Nalamasu R, Pergolizzi JV, et al. Pain Management During the COVID-19 Pandemic. Pain Ther. 2020;9:453-466. https://doi.org/10.1007/s40122-020-00190-4
Moutal A, Martin LF, Boinon L, Gomez K, Ran D, Zhou Y, et al. SARS-CoV-2 spike protein co-opts VEGF-A/neuropilin-1 receptor signaling to induce analgesia. Pain. 2021;162:243-252. https://doi.org/10.1097/j.pain.0000000000002097
Putilina MV. Peculiarities of asthenic disorders therapy, neurology and rheumatology. Supplement to the Journal Consilicum Medicum. 2010;1:30-35.
Putilina MV, Teplova NV. Medicinal safety as a priority area of domestic medicine. General Medicine. 2019;4:7-14. (In Russ.). https://doi.org/10.24411/2071-5315-2019-12152